Fujirebio
Fujirebio is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. Fujirebio was the first company to develop and market CSF biomarkers for Alzheimer’s Disease under the Innogenetics brand over 25 years ago. Most recently, it received the first FDA 510(k) clearance for a fully automated blood-based IVD test in the U.S. The company offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools.
